Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogen (NEOG) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Neogen (NEOG) over the last 3 years, with Q2 2025 value amounting to $597.9 million.

  • Neogen's Asset Writedowns and Impairment rose 10743866.91% to $597.9 million in Q2 2025 from the same period last year, while for May 2025 it was $599.9 million, marking a year-over-year increase of 9232973.81%. This contributed to the annual value of $1.1 billion for FY2025, which is 19212068.35% up from last year.
  • As of Q2 2025, Neogen's Asset Writedowns and Impairment stood at $597.9 million, which was up 10743866.91% from $2.1 million recorded in Q1 2025.
  • Neogen's 5-year Asset Writedowns and Impairment high stood at $597.9 million for Q2 2025, and its period low was -$716000.0 during Q1 2024.
  • For the 3-year period, Neogen's Asset Writedowns and Impairment averaged around $120.1 million, with its median value being $809000.0 (2023).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 3127.32% in 2024, then soared by 10743866.91% in 2025.
  • Neogen's Asset Writedowns and Impairment (Quarter) stood at $809000.0 in 2023, then plummeted by 31.27% to $556000.0 in 2024, then surged by 107438.67% to $597.9 million in 2025.
  • Its Asset Writedowns and Impairment was $597.9 million in Q2 2025, compared to $2.1 million in Q1 2025 and $556000.0 in Q2 2024.